Summary of opinion: Keytruda,pembrolizumab, 12/10/2023, Positive

Summary of opinion: Rubraca,rucaparib, 12/10/2023, Positive

Summary of opinion: Jemperli,dostarlimab, 12/10/2023, Positive

Summary of opinion: Elucirem,Gadopiclenol, 12/10/2023, Positive

Human medicines European public assessment report (EPAR): Ranivisio, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications, Date of authorisation: 25/08/2022, Revision: 4, Status: Authorised

Clinical Trials Information System (CTIS): Information day, Online, 13:30- 17:30 Amsterdam time (CET), from 17/10/2023 to 17/10/2023

Human medicines European public assessment report (EPAR): Xevudy, sotrovimab, COVID-19 virus infection, Date of authorisation: 17/12/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Farydak, panobinostat, Multiple Myeloma, Date of authorisation: 28/08/2015, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Rekambys, rilpivirine, HIV Infections, Date of authorisation: 17/12/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Wegovy , semaglutide, Obesity;Overweight, Date of authorisation: 06/01/2022, Revision: 4, Status: Authorised